8-K: Reviva Pharmaceuticals Reports Full Year 2024 Financial Results and Provides Business Update

Reviva Pharmaceuticals announces its full year 2024 financial results, highlighting positive clinical data from its brilaroxazine program and outlining anticipated milestones.

Summary

• Reviva Pharmaceuticals reported its full year 2024 financial results on March 31, 2025.
• The company is focused on developing therapies for central nervous system (CNS), inflammatory, and cardiometabolic diseases.
• A key program is brilaroxazine, which has shown robust broad-spectrum efficacy across major schizophrenia symptom domains and a well-tolerated safety profile.
• Preliminary topline data from the Phase 3 RECOVER study's open-label extension (OLE) showed sustained efficacy over one year, with PANSS total scores decreasing by 15.2, 18.6, and 20.8 points at 15, 30, and 50 mg doses, respectively.
• Pooled data from the OLE study demonstrated clinically meaningful and sustained long-term efficacy for schizophrenia, with significant decreases in PANSS total, positive, and negative symptoms scores.
• The company completed a public follow-on offering in December 2024, raising approximately $18.0 million in gross proceeds.
• Reviva anticipates initiating the registrational Phase 3 RECOVER-2 trial in mid-2025, subject to additional financing.
• A potential New Drug Application (NDA) submission for brilaroxazine in schizophrenia is targeted for the fourth quarter of 2026.
• The company reported a net loss of approximately $29.9 million, or $0.90 per share, for the fiscal year ended December 31, 2024, compared to a net loss of approximately $39.3 million, or $1.65 per share, for the fiscal year ended December 31, 2023.
• As of December 31, 2024, the company's cash and cash equivalents totaled approximately $13.5 million, compared to approximately $23.4 million as of December 31, 2023.

Sentiment

Score: 7

Explanation: The document presents a mixed picture. Positive clinical trial results and a follow-on offering are encouraging, but the net loss and decreased cash reserves raise concerns. The sentiment is cautiously optimistic.

Positives

• Brilaroxazine shows sustained efficacy and a favorable safety profile in treating schizophrenia.
• The company has a robust data package for brilaroxazine, including successful Phase 3 and Phase 2 trials.
• The company completed a follow-on offering, raising $18.0 million.
• The net loss decreased from 2023 to 2024, indicating improved financial performance.

Negatives

• The company experienced a net loss of $29.9 million in 2024.
• Cash and cash equivalents decreased from $23.4 million in 2023 to $13.5 million in 2024.
• The initiation of the Phase 3 RECOVER-2 trial is subject to receipt of additional financing.

Risks

• The company's ability to initiate the Phase 3 RECOVER-2 trial is contingent on securing additional financing.
• The NDA submission for brilaroxazine is targeted for Q4 2026, which is subject to regulatory review and potential delays.
• The company's cash reserves have decreased, raising concerns about its ability to fund ongoing operations and clinical trials.
• Clinical trials may not yield the desired results, which could impact the company's ability to obtain regulatory approval and commercialize its products.

Future Outlook

The company anticipates initiating the Phase 3 RECOVER-2 trial in mid-2025, subject to additional financing, and targets a potential NDA submission for brilaroxazine in schizophrenia in Q4 2026. They also plan to pursue partnership opportunities and submit an IND for a liposomal-gel formulation of brilaroxazine in psoriasis later in 2025.

Management Comments

• Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva, stated that brilaroxazine has consistently shown robust broad-spectrum efficacy and a well-tolerated safety profile.
• Dr. Bhat also mentioned that initial long-term data from the OLE study showed that these favorable efficacy and safety findings were sustained over time.
• Dr. Bhat believes the differentiated potential of once daily brilaroxazine to address all major unmet needs for patients with schizophrenia continues to be strong.

Industry Context

Reviva's focus on developing therapies for CNS disorders aligns with the growing need for innovative treatments in this area. The schizophrenia market, in particular, has significant unmet needs, and the positive data from brilaroxazine's clinical trials positions the company as a potential player in this space. The company's focus on partnership opportunities is a common strategy in the biotech industry to leverage resources and expertise for drug development and commercialization.

Comparison to Industry Standards

• The reported decrease in PANSS scores in Reviva's brilaroxazine trials is comparable to results seen in clinical trials for other atypical antipsychotics used in the treatment of schizophrenia, such as olanzapine (Zyprexa) and risperidone (Risperdal).
• The discontinuation rate of 35% in the OLE study, with only 1.6% due to treatment-related adverse events, suggests a favorable tolerability profile compared to some other antipsychotics, which can have higher discontinuation rates due to side effects.
• The targeted NDA submission in Q4 2026 is a typical timeline for a drug in late-stage development, assuming successful completion of Phase 3 trials and positive regulatory review.
• Reviva's cash position of $13.5 million is relatively low for a company planning to initiate a Phase 3 trial, and securing additional financing will be crucial for its continued development efforts. Many comparable companies have partnerships with larger pharmaceutical companies to share the costs and risks of late-stage development.

Stakeholder Impact

• Positive clinical trial results could lead to improved treatment options for patients with schizophrenia.
• Successful development and commercialization of brilaroxazine could benefit shareholders through increased stock value.
• Employees may benefit from the company's growth and expansion.

Next Steps

• Conduct full data analysis of the OLE trial, including vocal and blood biomarker data, expected in Q2 2025.
• Initiate registrational Phase 3 RECOVER-2 trial evaluating brilaroxazine for the treatment of schizophrenia, expected in mid-2025, subject to receipt of additional financing.
• Pursue partnership opportunities for the development of the pipeline.
• Submit an investigational new drug application (IND) for liposomal-gel formulation of brilaroxazine in psoriasis later in 2025.
• Target a potential NDA submission for brilaroxazine in schizophrenia for the fourth quarter of 2026.

Key Dates

Keywords

brilaroxazine, schizophrenia, clinical trials, RECOVER study, Phase 3, NDA submission, financial results, Reviva Pharmaceuticals, CNS, pharmaceuticals